[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100554736":3},{"organization":4,"outcomesModule":7,"designInfo":19,"detailedDescription":18,"studyPopulation":18,"armGroups":31,"interventions":46,"overallOfficials":18,"centralContacts":63,"locations":68,"responsibleParty":225,"collaborators":18,"id":227,"slug":18,"hasResults":228,"nctId":229,"briefTitle":230,"officialTitle":231,"acronym":18,"eligibilityCriteria":232,"healthyVolunteers":228,"sex":233,"minAge":234,"maxAge":235,"enrollmentInfo":236,"targetDuration":18,"studyType":239,"phases":240,"briefSummary":242,"conditions":243,"keywords":18,"overallStatus":71,"whyStopped":18,"lastUpdateSubmitDate":246,"lastUpdatePostDateStruct":247,"startDateStruct":250,"completionDateStruct":252,"leadSponsor":254,"locationsCount":255},{"fullName":5,"class":6},"Alto Neuroscience","INDUSTRY",{"primaryOutcomes":8,"secondaryOutcomes":13,"otherOutcomes":18},[9],{"measure":10,"description":11,"timeFrame":12},"Theta band activity","Theta band activity after 5 and 10 days of dosing of ALTO-101T compared to placebo.","Treatment Period 1 - Day 6 and Day 11; Treatment Period 2 - Day 6 and Day 11",[14],{"measure":15,"description":16,"timeFrame":17},"Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability] ALTO-101T compared to placebo","Incidence, severity, and relatedness of treatment-emergent adverse events (TEAEs), serious adverse events (SAEs), and discontinuation due to TEAEs.","Treatment Period Day 1 through study completion (an average of 36 days)",null,{"allocation":20,"interventionModel":21,"interventionModelDescription":22,"primaryPurpose":23,"observationalModel":18,"timePerspective":18,"maskingInfo":24},"RANDOMIZED","CROSSOVER","Each participant will receive both placebo and active study drug: 10-day administration each of placebo TDS and ALTO-101T TDS (in random order), with a 6- to 14-day washout period between conditions.","TREATMENT",{"masking":25,"maskingDescription":18,"whoMasked":26},"QUADRUPLE",[27,28,29,30],"PARTICIPANT","CARE_PROVIDER","INVESTIGATOR","OUTCOMES_ASSESSOR",[32,39],{"label":33,"type":34,"description":35,"interventionNames":36},"ALTO-101","EXPERIMENTAL","10 days administration of ALTO-101T transdermal delivery system",[37,38],"Drug: ALTO-101","Device: ALTO-101 Transdermal Delivery System",{"label":40,"type":41,"description":42,"interventionNames":43},"Placebo","PLACEBO_COMPARATOR","10 days administration of placebo transdermal delivery system",[44,45],"Drug: Placebo","Device: Placebo Transdermal Delivery System",[47,51,56,59],{"type":48,"name":33,"description":49,"armGroupLabels":50,"otherNames":18},"DRUG","ALTO-101 patches",[33],{"type":52,"name":53,"description":54,"armGroupLabels":55,"otherNames":18},"DEVICE","ALTO-101 Transdermal Delivery System","ALTO-101 transdermal delivery system",[33],{"type":48,"name":40,"description":57,"armGroupLabels":58,"otherNames":18},"Inactive placebo patches",[40],{"type":52,"name":60,"description":61,"armGroupLabels":62,"otherNames":18},"Placebo Transdermal Delivery System","Placebo transdermal delivery system",[40],[64],{"name":5,"role":65,"phone":66,"phoneExt":18,"email":67},"CONTACT","650-200-0412","clinical@altoneuroscience.com",[69,86,97,108,119,131,140,152,164,176,188,199,207,214],{"facility":70,"status":71,"city":72,"state":73,"zip":74,"country":75,"countryCode":76,"cosmosGeoPoint":77,"geoPoint":82,"contacts":83},"Site 5038","RECRUITING","Garden Grove","California","92845","United States","US",{"type":78,"coordinates":79},"Point",[80,81],-117.94145,33.77391,{"lat":81,"lon":80},[84],{"name":85,"role":65,"phone":18,"phoneExt":18,"email":18},"Clinical Operations Manager",{"facility":87,"status":71,"city":88,"state":73,"zip":89,"country":75,"countryCode":76,"cosmosGeoPoint":90,"geoPoint":94,"contacts":95},"Site 5063","Los Angeles","90015",{"type":78,"coordinates":91},[92,93],-118.24368,34.05223,{"lat":93,"lon":92},[96],{"name":85,"role":65,"phone":18,"phoneExt":18,"email":18},{"facility":98,"status":71,"city":99,"state":73,"zip":100,"country":75,"countryCode":76,"cosmosGeoPoint":101,"geoPoint":105,"contacts":106},"Site 5106","Orange","92868",{"type":78,"coordinates":102},[103,104],-117.85311,33.78779,{"lat":104,"lon":103},[107],{"name":85,"role":65,"phone":18,"phoneExt":18,"email":18},{"facility":109,"status":71,"city":110,"state":73,"zip":111,"country":75,"countryCode":76,"cosmosGeoPoint":112,"geoPoint":116,"contacts":117},"Site 5035","Walnut Creek","94596",{"type":78,"coordinates":113},[114,115],-122.06496,37.90631,{"lat":115,"lon":114},[118],{"name":85,"role":65,"phone":18,"phoneExt":18,"email":18},{"facility":120,"status":71,"city":121,"state":122,"zip":123,"country":75,"countryCode":76,"cosmosGeoPoint":124,"geoPoint":128,"contacts":129},"Site 5060","Hollywood","Florida","33024",{"type":78,"coordinates":125},[126,127],-80.14949,26.0112,{"lat":127,"lon":126},[130],{"name":85,"role":65,"phone":18,"phoneExt":18,"email":18},{"facility":132,"status":71,"city":133,"state":122,"zip":134,"country":75,"countryCode":76,"cosmosGeoPoint":135,"geoPoint":139,"contacts":18},"Site 5015","Tampa","33629",{"type":78,"coordinates":136},[137,138],-82.45843,27.94752,{"lat":138,"lon":137},{"facility":141,"status":71,"city":142,"state":143,"zip":144,"country":75,"countryCode":76,"cosmosGeoPoint":145,"geoPoint":149,"contacts":150},"Site 5064","Snellville","Georgia","30078",{"type":78,"coordinates":146},[147,148],-84.01991,33.85733,{"lat":148,"lon":147},[151],{"name":85,"role":65,"phone":18,"phoneExt":18,"email":18},{"facility":153,"status":71,"city":154,"state":155,"zip":156,"country":75,"countryCode":76,"cosmosGeoPoint":157,"geoPoint":161,"contacts":162},"Site 5056","Chicago","Illinois","60640",{"type":78,"coordinates":158},[159,160],-87.65005,41.85003,{"lat":160,"lon":159},[163],{"name":85,"role":65,"phone":18,"phoneExt":18,"email":18},{"facility":165,"status":71,"city":166,"state":167,"zip":168,"country":75,"countryCode":76,"cosmosGeoPoint":169,"geoPoint":173,"contacts":174},"Site 5062","Gaithersburg","Maryland","20877",{"type":78,"coordinates":170},[171,172],-77.20137,39.14344,{"lat":172,"lon":171},[175],{"name":85,"role":65,"phone":18,"phoneExt":18,"email":18},{"facility":177,"status":71,"city":178,"state":179,"zip":180,"country":75,"countryCode":76,"cosmosGeoPoint":181,"geoPoint":185,"contacts":186},"Site 5124","Belmont","Massachusetts","02478",{"type":78,"coordinates":182},[183,184],-71.17867,42.39593,{"lat":184,"lon":183},[187],{"name":85,"role":65,"phone":18,"phoneExt":18,"email":18},{"facility":189,"status":71,"city":190,"state":190,"zip":191,"country":75,"countryCode":76,"cosmosGeoPoint":192,"geoPoint":196,"contacts":197},"Site 5108","New York","10027",{"type":78,"coordinates":193},[194,195],-74.00597,40.71427,{"lat":195,"lon":194},[198],{"name":85,"role":65,"phone":18,"phoneExt":18,"email":18},{"facility":200,"status":71,"city":190,"state":190,"zip":201,"country":75,"countryCode":76,"cosmosGeoPoint":202,"geoPoint":204,"contacts":205},"Site 5077","10032",{"type":78,"coordinates":203},[194,195],{"lat":195,"lon":194},[206],{"name":85,"role":65,"phone":18,"phoneExt":18,"email":18},{"facility":208,"status":209,"city":190,"state":190,"zip":210,"country":75,"countryCode":76,"cosmosGeoPoint":211,"geoPoint":213,"contacts":18},"Site 5109","WITHDRAWN","10035",{"type":78,"coordinates":212},[194,195],{"lat":195,"lon":194},{"facility":215,"status":71,"city":216,"state":190,"zip":217,"country":75,"countryCode":76,"cosmosGeoPoint":218,"geoPoint":222,"contacts":223},"Site 5126","White Plains","10605",{"type":78,"coordinates":219},[220,221],-73.76291,41.03399,{"lat":221,"lon":220},[224],{"name":85,"role":65,"phone":18,"phoneExt":18,"email":18},{"type":226,"investigatorFullName":18,"investigatorTitle":18,"investigatorAffiliation":18,"oldNameTitle":18,"oldOrganization":18},"SPONSOR","100554736",false,"NCT06502964","Study of ALTO-101 in Patients With Schizophrenia","Double-Blind, Placebo-Controlled Study of ALTO-101 in Patients With Schizophrenia and Cognitive Impairment","Inclusion Criteria:\n\n* Schizophrenia diagnosis for at least one year\n* Cognitive impairment\n* Stable doses of 1-2 antipsychotic medication(s) for at least 8 weeks at Visit 2\n* Positive and Negative Syndrome Scale (PANSS) score: items P1, P3-P6 ≤ 5 and item P2 and P7 ≤ 4 during screening\n* Have a body mass index (BMI) ≥ 18.0 and ≤ 37.0 kg\u002Fm2 (inclusive)\n* Willing to comply with all study assessments and procedures\n\nExclusion Criteria:\n\n* Evidence of unstable medical condition\n* Acute psychiatric decompensation or severity of symptoms requiring psychiatric hospitalization in past 6 months\n* Diagnosis of schizoaffective or bipolar affective disorder, dementia, or intellectual disability\n* Current episode of major depressive disorder (MDD)\n* Use of mood stabilizer, clozapine, and\u002For daily benzodiazepine\n* Current moderate or severe substance use disorder","ALL","21 Years","55 Years",{"count":237,"type":238},82,"ESTIMATED","INTERVENTIONAL",[241],"PHASE2","This is a Phase 2, double-blind, placebo-controlled, two-way crossover study to compare the efficacy of ALTO-101T versus placebo in change in electroencephalogram (EEG) cognitive processing markers and measures of cognition.\n\nAdditional goals are to assess pharmacokinetic (PK), safety, and tolerability of the recently developed ALTO-101T transdermal delivery system (TDS) formulation in a patient population.",[244,245],"Schizophrenia","Cognitive Impairment","2025-12-23",{"date":248,"type":249},"2025-12-26","ACTUAL",{"date":251,"type":249},"2024-06-11",{"date":253,"type":238},"2026-03",{"name":5,"class":6},14]